Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Sells 6,000 Shares of Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Iqbal J. Hussain sold 6,000 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $16.18, for a total value of $97,080.00. Following the completion of the transaction, the general counsel now owns 105,386 shares in the company, valued at approximately $1,705,145.48. This represents a 5.39 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Centessa Pharmaceuticals Price Performance

CNTA opened at $15.91 on Thursday. Centessa Pharmaceuticals plc has a 1 year low of $7.75 and a 1 year high of $19.09. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The company has a market capitalization of $2.10 billion, a price-to-earnings ratio of -10.40 and a beta of 1.53. The firm’s fifty day moving average price is $16.71 and its two-hundred day moving average price is $15.78.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. TD Cowen initiated coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating on the stock. Guggenheim reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Monday, February 10th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $25.83.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in CNTA. Mirae Asset Global Investments Co. Ltd. grew its position in Centessa Pharmaceuticals by 47.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after purchasing an additional 826 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Centessa Pharmaceuticals by 99.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company’s stock valued at $217,000 after acquiring an additional 6,785 shares in the last quarter. Atria Investments Inc increased its position in shares of Centessa Pharmaceuticals by 7.0% during the third quarter. Atria Investments Inc now owns 17,134 shares of the company’s stock valued at $274,000 after acquiring an additional 1,116 shares during the last quarter. GSA Capital Partners LLP lifted its holdings in Centessa Pharmaceuticals by 66.1% during the third quarter. GSA Capital Partners LLP now owns 93,658 shares of the company’s stock worth $1,498,000 after acquiring an additional 37,275 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its position in Centessa Pharmaceuticals by 88.1% in the third quarter. The Manufacturers Life Insurance Company now owns 264,969 shares of the company’s stock worth $4,237,000 after purchasing an additional 124,075 shares during the last quarter. 82.01% of the stock is owned by institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.